Spectrum Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Spectrum Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Spectrum Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Spectrum Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Spectrum Pharmaceuticals, Inc.

The report provides overview of Spectrum Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Spectrum Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Spectrum Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Spectrum Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Spectrum Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Spectrum Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Spectrum Pharmaceuticals, Inc. Snapshot 6

Spectrum Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Spectrum Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Spectrum Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Spectrum Pharmaceuticals, Inc. - Pipeline Products Glance 14

Spectrum Pharmaceuticals, Inc. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Spectrum Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Spectrum Pharmaceuticals, Inc. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Spectrum Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 19

Unknown Products/Combination Treatment Modalities 19

Spectrum Pharmaceuticals, Inc. - Drug Profiles 20

apaziquone 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

vincristine sulfate 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

eflapegrastim 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

belinostat 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

menadione sodium bisulfite 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ozarelix 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

poziotinib 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

pralatrexate 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

SPI-014 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

SPI-1620 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Alocrest 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

MTRN-2696 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

SPI-205 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

topotecan hydrochloride 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

melphalan 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Yttritum 90 ibritumomab tiuxetan 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Spectrum Pharmaceuticals, Inc. - Pipeline Analysis 49

Spectrum Pharmaceuticals, Inc. - Pipeline Products by Target 49

Spectrum Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 51

Spectrum Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 52

Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 53

Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates 55

Spectrum Pharmaceuticals, Inc. - Dormant Projects 76

Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products 77

Discontinued Pipeline Product Profiles 77

efaproxiral 77

ortataxel 77

RH-1 77

Spectrum Pharmaceuticals, Inc. - Company Statement 78

Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

Spectrum Pharmaceuticals, Inc., Key Information 6

Spectrum Pharmaceuticals, Inc., Key Facts 6

Spectrum Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Spectrum Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Spectrum Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Spectrum Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Spectrum Pharmaceuticals, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13

Spectrum Pharmaceuticals, Inc. – Pre-Registration, 2016 14

Spectrum Pharmaceuticals, Inc. – Phase III, 2016 15

Spectrum Pharmaceuticals, Inc. – Phase II, 2016 16

Spectrum Pharmaceuticals, Inc. – Phase I, 2016 17

Spectrum Pharmaceuticals, Inc. – Preclinical, 2016 18

Spectrum Pharmaceuticals, Inc. – Unknown, 2016 19

Spectrum Pharmaceuticals, Inc. – Pipeline by Target, 2016 49

Spectrum Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 51

Spectrum Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 52

Spectrum Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 54

Spectrum Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 55

Spectrum Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 76

Spectrum Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 77

Spectrum Pharmaceuticals, Inc., Other Locations 79

Spectrum Pharmaceuticals, Inc., Subsidiaries 79

List of Figures

List of Figures

Spectrum Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Spectrum Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Spectrum Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Spectrum Pharmaceuticals, Inc. – Partnered Products in Pipeline, 2016 12

Spectrum Pharmaceuticals, Inc. – Pipeline by Top 10 Target, 2016 49

Spectrum Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 51

Spectrum Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 52

Spectrum Pharmaceuticals, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 53

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports